



High-throughput mutational analysis of TOR1A in primary dystonia

Citation

Xiao, Jianfeng, Robert W. Bastian, Joel S. Perlmutter, Brad A. Racette, Samer D. Tabbal, Morvarid Karimi, Randal C. Paniello, et al. 2009. High-throughput mutational analysis of TOR1A in primary dystonia. BMC Medical Genetics 10: 24.

Published Version

doi:10.1186/1471-2350-10-24

Permanent link

<http://nrs.harvard.edu/urn-3:HUL.InstRepos:4879199>

Terms of Use

This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA>

Share Your Story

The Harvard community has made this article openly available.
Please share how this access benefits you. [Submit a story](#).

[Accessibility](#)

Research article

Open Access

High-throughput mutational analysis of *TOR1A* in primary dystonia

Jianfeng Xiao¹, Robert W Bastian², Joel S Perlmuter³, Brad A Racette³, Samer D Tabbal³, Morvarid Karimi³, Randal C Paniello³, Andrew Blitzer⁴, Sat Dev Batish⁵, Zbigniew K Wszolek⁶, Ryan J Uitti⁶, Peter Hedera⁷, David K Simon⁸, Daniel Tarsy⁸, Daniel D Truong⁹, Karen P Frei⁹, Ronald F Pfeiffer¹, Suzhen Gong¹, Yu Zhao¹ and Mark S LeDoux*¹

Address: ¹Departments of Neurology and Anatomy & Neurobiology, University of Tennessee Health Science Center, Memphis, TN, USA, ²Bastian Voice Institute, Downers Grove, IL, USA, ³Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA, ⁴New York Center for Voice and Swallowing Disorders, New York, NY, USA, ⁵Athena Diagnostics, Inc., Worcester, MA, USA, ⁶Department of Neurology, Mayo Clinic, Jacksonville, FL, USA, ⁷Department of Neurology, Vanderbilt University, Nashville, TN, USA, ⁸Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA and ⁹Parkinson's & Movement Disorder Institute, Fountain Valley, CA, USA

Email: Jianfeng Xiao - jianfengxiao@gmail.com; Robert W Bastian - robert.bastian@bastianvoice.com; Joel S Perlmuter - joel@npg.wustl.edu; Brad A Racette - racetteb@neuro.wustl.edu; Samer D Tabbal - tabbals@neuro.wustl.edu; Morvarid Karimi - morvaridk@npg.wustl.edu; Randal C Paniello - paniellor@ent.wustl.edu; Andrew Blitzer - Ab1136@aol.com; Sat Dev Batish - dev.batish@athenadiagnostics.com; Zbigniew K Wszolek - Wszolek.Zbigniew@mayo.edu; Ryan J Uitti - uitti@mayo.edu; Peter Hedera - peter.hedera@vanderbilt.edu; David K Simon - dsimon1@bidmc.harvard.edu; Daniel Tarsy - dtarsy@bidmc.harvard.edu; Daniel D Truong - dtruong@pmdi.org; Karen P Frei - kfrei@pmdi.org; Ronald F Pfeiffer - rpfeiffer@utmem.edu; Suzhen Gong - sgong@utmem.edu; Yu Zhao - yzhao3@utmem.edu; Mark S LeDoux* - mledoux@utmem.edu

* Corresponding author

Published: 11 March 2009

Received: 7 December 2008

BMC Medical Genetics 2009, 10:24 doi:10.1186/1471-2350-10-24

Accepted: 11 March 2009

This article is available from: <http://www.biomedcentral.com/1471-2350/10/24>

© 2009 Xiao et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: Although the c.904_906delGAG mutation in Exon 5 of *TOR1A* typically manifests as early-onset generalized dystonia, DYT1 dystonia is genetically and clinically heterogeneous. Recently, another Exon 5 mutation (c.863G>A) has been associated with early-onset generalized dystonia and some ΔGAG mutation carriers present with late-onset focal dystonia. The aim of this study was to identify *TOR1A* Exon 5 mutations in a large cohort of subjects with mainly non-generalized primary dystonia.

Methods: High resolution melting (HRM) was used to examine the entire *TOR1A* Exon 5 coding sequence in 1014 subjects with primary dystonia (422 spasmodic dysphonia, 285 cervical dystonia, 67 blepharospasm, 41 writer's cramp, 16 oromandibular dystonia, 38 other primary focal dystonia, 112 segmental dystonia, 16 multifocal dystonia, and 17 generalized dystonia) and 250 controls (150 neurologically normal and 100 with other movement disorders). Diagnostic sensitivity and specificity were evaluated in an additional 8 subjects with known ΔGAG DYT1 dystonia and 88 subjects with ΔGAG-negative dystonia.

Results: HRM of *TOR1A* Exon 5 showed high (100%) diagnostic sensitivity and specificity. HRM was rapid and economical. HRM reliably differentiated the *TOR1A* ΔGAG and c.863G>A mutations. Melting curves were normal in 250/250 controls and 1012/1014 subjects with primary dystonia. The two subjects with shifted melting curves were found to harbor the classic ΔGAG deletion: 1)

a non-Jewish Caucasian female with childhood-onset multifocal dystonia and 2) an Ashkenazi Jewish female with adolescent-onset spasmodic dysphonia.

Conclusion: First, HRM is an inexpensive, diagnostically sensitive and specific, high-throughput method for mutation discovery. Second, Exon 5 mutations in *TOR1A* are rarely associated with non-generalized primary dystonia.

Background

Dystonia is a syndrome of sustained muscle contractions, frequently causing twisting and repetitive movements, or abnormal postures [1]. Dystonia can be classified by etiology (primary or secondary), age of onset (childhood-onset [0–12 yrs], adolescent-onset [13–20 yrs], or late-onset [>20 yrs]), and anatomical distribution (focal, segmental, multifocal, hemidystonia, or generalized) [1–4]. Primary generalized dystonias usually begin in childhood or adolescence, whereas focal dystonias typically present during adult life. Primary dystonia includes syndromes in which dystonia is the sole phenotypic manifestation, with the exception that tremor may be present as well.

In most neurology subspecialty practices, the vast majority of patients with dystonia are adults with primary focal or segmental disease. Genetic factors likely play a major role in late-onset primary dystonia since 8–27% of patients with primary late-onset dystonia have one or more family members affected with dystonia [5–9] and several of the primary dystonias inherited in Mendelian fashion (*DYT1*, *DYT5*, *DYT6*, *DYT11*, and *DYT12*) begin focally, show incomplete penetrance and exhibit variable anatomical expressivity [10–12]. These facts suggest that sporadic late-onset dystonia, much like Parkinson's disease, is a complex disorder with contributions from multiple genes and environmental factors. Candidate gene studies have been successful in several late-onset neurological disorders, particularly Parkinson's disease, and may be fruitful in primary dystonia. Late-onset sporadic dystonia could be associated with a number of distinct mutations of low penetrance.

The Δ GAG (c.904_906delGAG) mutation in Exon 5 of *TOR1A* is characteristically associated with early-onset generalized dystonia [13]. Although infrequent, the *DYT1* Δ GAG mutation has also been associated with late-onset focal, segmental, and multifocal dystonia [14–19]. Another mutation in Exon 5 of *TOR1A* (c.863G>A) has been described in a female patient with severe childhood-onset generalized dystonia [20]. The G>A transition in Exon 5 results in exchange of an arginine for glutamine. In contrast to the *DYT1* Δ GAG mutation, analysis of late-onset dystonia cases for the c.863G>A mutation has not been described to date. Two additional mutations have been described in Exon 5, the terminal exon of *TOR1A*. Leung and colleagues [21] reported a patient with early-onset dys-

tonia and myoclonus who harbored an 18-bp deletion in Exon 5 which should eliminate 6 amino acids near the carboxy terminus of torsinA (Phe323_Tyr328del), including a putative phosphorylation site. The causality of the 18-bp deletion is unclear since the same subject was subsequently found to have an *SGCE* mutation [22]. As described in another study, a novel out-of-frame 4-bp deletion (c.934_937delAGAG) found in a putatively healthy blood donor should result in an alteration of amino acids starting at position 312 with a premature stop at position 325 (E312/Stop325) in the carboxy terminus of torsinA [18].

To help address the role of the *TOR1A* gene in non-generalized primary dystonia, we used high resolution melting (HRM) to examine the entire *TOR1A* Exon 5 coding sequence in a large cohort of patients with non-generalized dystonia. HRM has been shown to be a fast and accurate, closed-tube, post-PCR mutation scanning technique that monitors the progressive change in fluorescence caused by the release of an intercalating DNA dye from DNA duplexes as they are denatured by minor increases in temperature [23]. Our results indicate that mutations in Exon 5 of *TOR1A* are rare in non-generalized primary dystonia.

Methods

Subjects

All human studies were performed in accordance with institutional review board guidelines and all subjects gave informed consent. Subjects with dystonia and neurologically-normal controls were acquired from outpatient clinics at participating institutions (University of Tennessee Health Science Center, Bastian Voice Institute, Washington University School of Medicine in St. Louis, New York Center for Voice and Swallowing Disorders, Mayo Clinic Jacksonville, Beth Israel Deaconess Medical Center, Vanderbilt University and the Parkinson's & Movement Disorder Institute) and support group meetings of the National Spasmodic Dysphonia Association (NSDA), National Spasmodic Torticollis Association (NSTA), Benign Essential Blepharospasm Research Foundation (BEBRF), Dystonia/Spasmodic Torticollis, and Dystonia Medical Research Foundation (DMRF). All subjects with dystonia acquired at support group meetings were examined by M.S.L. Subjects with Parkinson's disease and other movement disorders were acquired from the clinics of M.S.L. and R.F.P. Clinical diagnoses and classifications were

made by means of history and examination by one or more neurologists and/or neurolaryngologist at each institution. Neurologically-normal control subjects were defined as individuals with no personal or first-degree family history of neurological disease. In addition, all control subjects acquired at the University of Tennessee Health Science Center and support group meetings were examined by M.S.L. or R.F.P. Dystonia was classified in accordance with established schemes [1,3,24]. Subjects with established diagnoses of DYT1 dystonia were not recruited into our study.

Clinical diagnoses for 1264 subjects interrogated with HRM appear in Table 1. Demographic information and dystonia distribution was not available for 96 DNA samples received from Athena Diagnostics, Inc. (Worcester, MA). The panel from Athena Diagnostics included 8 samples with confirmed DYT1 Δ GAG deletions and 88 Δ GAG-negative samples associated with a clinical diagnosis of "dystonia."

DNA

DNA was extracted from peripheral blood leucocytes using Roche's DNA Isolation Kit for Mammalian Blood (Roche Applied Science, Indianapolis, IN). DNA quantity and quality were analyzed with a NanoDrop ND-100 spectrophotometer (NanoDrop Technologies LLC, Wilmington, DE), Quant-iT™ PicoGreen® dsDNA Assay Kit (Invitrogen Inc. Carlsbad, CA) and agarose gel electrophoresis. High-quality DNA samples were diluted with PCR water to a concentration of 10 ng/μl. Poor quality samples were rescued by whole genome amplification with the REPLI-g® Mini Kit from Qiagen (Valencia, CA). Samples that could not be rescued were not used for HRM and do not appear in Table 1.

HRM

Using Primer3 (frodo.wi.mit.edu), a pair of PCR primers was designed to cover the entire *TOR1A* Exon 5 coding sequence (forward: cagcacctgtttcttcttcc, reverse: ccaactcaggcagtgactc). Another forward primer was synthesized for site-directed mutagenesis of Exon 5 to generate the c.863G>A mutation (aacagcacctgtttcttcttccagggtggcttctggcacagcagcttaattgaccggaacctcattgattatttggcttctctccctggaatacaaacacctaataatgtgtatccgagtggaaatgcagctcccAaggctatga). To evaluate HRM results with amplicons of different sizes, a pair of previously-published primers was used to amplify the DYT1 Δ GAG region of Exon 5 [13].

The LightCycler® 480 Real-Time PCR system and High Resolution Master Mix from Roche Applied Science (Indianapolis, IN, USA) were used for HRM. The master mix contains the LightCycler 480 ResoLight Dye. The High Resolution Melting Master Mix is a ready-to-use hot-start

mix designed for PCR amplification followed by HRM curve analysis for detection of sequence variants. ResoLight, a novel saturating DNA dye, was specifically designed for detection of sequence variations by differences in melting curves. ResoLight can be used at high concentrations without inhibiting PCR and its homogeneous staining of target sequences results in sharp melting signals. As the temperature of the solution is increased during HRM, the specific sequence of the amplicon (primarily GC content and length) determines the melting behavior. When the fluorescence signal is plotted against temperature, fluorescence intensity decreases as double-stranded DNA (dsDNA) becomes single stranded and ResoLight is released. Since melting point (T_M) differences are often too small for reliable differentiation of amplicons, separation is achieved by signal normalization and temperature shifting (Fig 1a, c, e, and 1g). For normalization, the pre- and post-melt signals are set to uniform relative values. For temperature shifting, the temperature axes of the normalized melting curves are shifted to the point where the entirety of dsDNA is denatured. The LightCycler 480 Gene Scanning Software detects differences in melting curves and allocates samples to groups of the same sequence. Finally, difference plots are created by subtracting melting curves from a reference curve (Fig 1b, d, f, and 1h).

The HRM Master Mix contains FastStart Taq DNA polymerase, reaction buffer, a dNTP mix and ResoLight. HRM was optimized to detect and differentiate the Δ GAG and c.863G>A mutations by adjusting reaction conditions and the concentrations of template DNA, primers and $MgCl_2$. To emulate the heterozygous state, a 1:1 mixture of normal DNA with c.863G>A amplicons was utilized for these reactions. Then, to define sensitivity and sensitivity, HRM was performed with the collection of 96 samples from Athena Diagnostics that included 8 samples with confirmed DYT1 Δ GAG deletions and 88 additional samples with a clinical diagnosis of "dystonia." Optimized reactions were performed in 96-well plates (Roche Catalog #04729692001) using 10–20 ng of template DNA, 1× HRM Master Mix, 2.5 mM $MgCl_2$ and 200 nM of each primer in a 20-μl reaction volume. PCR cycling and HRM conditions were carried out as follows: 95°C for 10 min; 45 cycles at 95°C for 10 s, 60°C for 15 s, and 72°C for 15 s; 95°C for 1 min, 40°C for 1 min, and the final HRM temperature ramp from 70°C to 95°C rising at 0.1°C/s. All subject samples and negative controls were run in duplicate using 96-well plates.

With LightCycler 480 Gene Scanning Software, melting curves and difference plots were analyzed by three investigators (S.G., Y.Z., and M.S.L.) blinded to phenotype. All samples were unambiguously assigned to one of three genotypes (wild-type or normal, Δ GAG deletion, or

Table 1: Clinical diagnoses and demographics

Clinical diagnosis	Number (age of onset) ^a	Family history ^b	Gender		Race/Ethnicity			TOR1A exon 5 mutations
			Male	Female	Non-Jewish Caucasian	Jewish	Other	
Spasmodic dysphonia	422 (45.0 ± 15.7, 7–84)	7.3%	91	331	368	2	52	1 ΔGAG
Cervical dystonia	285 (43.7 ± 13.8, 4–76)	8.4%	71	214	268	1	16	0
Blepharospasm	67 (54.4 ± 10.1, 20–73)	10.4%	20	47	61	2	4	0
Writer's cramp	41 (35.3 ± 14.4, 7–60)	7.3%	17	24	35	0	6	0
Oromandibular dystonia	16 (48.9 ± 15.4, 20–70)	6.3%	3	13	13	1	2	0
Other primary focal dystonia	38 (37.8 ± 18.2, 10–74)	5.3%	14	24	34	0	4	0
Segmental dystonia	112 (48.7 ± 12.8, 14–74)	13.4%	39	73	101	0	11	0
Multifocal dystonia	16 (30.0 ± 15.9, 7–67)	25.0%	3	13	15	0	1	1 ΔGAG
Generalized dystonia	17 (18.2 ± 15.3, 1–57)	0.0%	7	10	17	0	0	0
Dystonia totals	1014 (44.3 ± 15.6, 1–84)	8.6%	265	749	912	6	96	2 GAG
Parkinson's disease	42 (63.0 ± 12.5, 28–82)	NA	19	23	39	0	3	0
Restless legs syndrome	31 (40.6 ± 18.3, 8–66)	NA	12	19	29	0	2	0
Essential tremor	14 (50.9 ± 15.4, 30–70)	NA	9	5	13	0	1	0
Other movement disorders	13 (49.8 ± 17.3, 27–71)	NA	9	4	12	0	1	0
Neurologically-normal controls	150 (56.5 ± 14.5, 23–83) ^c	NA	79	71	135	0	15	0
ΔGAG-negative dystonia	88 (NA)	NA	NA	NA	NA	NA	NA	0
ΔGAG DYT1 dystonia	8 (NA)	NA	NA	NA	NA	NA	NA	8 ΔGAG
Grand totals	1360							10 ΔGAG

^aMean +/- standard error, range (yrs).^bFirst- or second-degree relative with dystonia.^cAge at study enrollment.

NA = not available or applicable.

c.863G>A mutation) by Gene Scanning Software. DNA from wells with abnormal melting curves was purified with the Qiagen QIAquick PCR Purification Kit. The Δ GAG deletion and c.863G>A mutations were confirmed by direct sequencing of purified PCR products in the forward and reverse directions using an ABI Prism 377 DNA Sequencer (Applied Biosystems, Foster City, CA, USA).

Results

HRM

As seen in Fig 1a and 1b, all 8 Δ GAG-positive samples were clearly differentiated from the 88 Δ GAG-negative samples; amplicons containing the Δ GAG mutation melted/denatured prior to the Δ GAG-negative samples. The Δ GAG-positive samples clustered together on the melting curves and difference plots with minimal sample-to-sample variation. Furthermore, segregation of Δ GAG-positive and Δ GAG-negative samples was maintained despite 25-fold variation in the concentrations of DNA templates from 0.1 ng/ μ l to 2.5 ng/ μ l (Fig 1c and 1d). No false positive or false negative samples were detected within this broad concentration range.

HRM robustly distinguished samples with either Δ GAG deletions or c.863G>A mutations from normals (Fig 1e–1h). Diagnostic sensitivity and diagnostic specificity for Δ GAG deletion and c.863G>A mutation were 100% with both primer pairs (Fig 1e–1h). As expected, the larger *TOR1A* Exon 5 amplicon (314 bp, Fig 1e and 1f) had a higher melting temperature (T_M = 83.2°C) than the smaller amplicon (205 bp, T_M = 81.2°C) which was generated with previously published primers [13].

LightCycler® 480 HRM Master Mix (Catalog #04909631001) was purchased for \$400 (<http://www.roche-applied-science.com>) and contained reagents for 500 reactions (20 μ l reaction volume, \$0.80/reaction). LightCycler® 480 Multiwell Plates 96, white with sealing foils (Catalog # 04729692001), must be used for HRM and were purchased for \$360/50 plates (\$7.20/plate). Excluding the costs of pipette tips and primers, 96 reactions were completed for \$84.00. On average, each plate was setup, run, and analyzed in 3 hrs.

***TOR1A* Exon 5 Mutations in Non-Generalized Primary Dystonia**

Two subjects (#1 and #2) with non-generalized primary dystonia were found to harbor the classic DYT1 Δ GAG deletion in Exon 5 of *TOR1A*. No *TOR1A* Exon 5 mutations or variants were identified in the remaining 1012 subjects with dystonia or 250 controls. Subject #1 with the classic DYT1 Δ GAG mutation exhibited multifocal dystonia. She was a 48-yr-old non-Jewish Caucasian female with cervical dystonia, spasmodic dysphonia (adductor subtype), and writer's cramp. Cervical dystonia became


manifest at 12 yrs of age whereas laryngeal involvement and writer's cramp became apparent at 39 and 45 yrs of age, respectively. She reported consistent benefit from injections of botulinum toxin type A for treatment of her laryngeal and cervical dystonia. Her mother had never been diagnosed with "dystonia" but reportedly exhibited action-induced "leg tremors." A maternal aunt (her mother's monozygotic twin) suffered from an undiagnosed voice disorder prior to her death. Subject #1 had two siblings, both brothers. By report, one brother was neurologically normal. The second brother developed generalized dystonia at 9 years of age and died at 16 years of age with respiratory complications.

Subject #2, also with the classic DYT1 Δ GAG mutation, was a 63-yr-old woman of Ashkenazi Jewish descent. She had spasmodic dysphonia (adductor subtype) that became manifest at 19 years of age. Injections of botulinum toxin type A achieved consistently excellent results over a period of 12 yrs. Subject #2 also exhibited a bilateral upper extremity action tremor (<2 cm excursions). She had one child who was neurologically normal. Her mother and maternal grandmother had received diagnoses of "essential tremor." None of her family members were available for neurological examination.

Discussion

In 2000, Bressman and colleagues published diagnostic testing guidelines for the DYT1 GAG deletion [25] and recommended DYT1 Δ GAG testing in conjunction with genetic counseling for subjects displaying primary dystonia with onset prior to 26 yrs of age. Testing may be warranted in subjects with onset after age 26 if they have an affected relative with early-onset primary dystonia [25]. Our results are entirely consistent with those guidelines. Although *de novo* Δ GAG mutations of *TOR1A* Exon 5 have been described [26,27], our findings indicate that they must be extraordinarily rare in non-generalized primary dystonia in the United States. Furthermore, we have shown that other *TOR1A* Exon 5 variants, including the recently described c.863G>A missense mutation, must also be rare in subjects with non-generalized primary dystonia.

As outlined in Table 2, the classic DYT1 Δ GAG mutation is uncommon in non-generalized primary dystonia and quite rare in late-onset primary dystonia. The typical DYT1 phenotype is characterized by early-onset in a limb, most commonly a leg, with spread to other limbs and the trunk over several years. Writer's cramp or more extensive upper limb dystonia without task-specificity is the most common presentation of adolescent- or late-onset primary dystonia due to the DYT1 Δ GAG mutation and most of these subjects will have a positive family history of dystonia [19]. However, DYT1 dystonia is phenotypically

**Figure 1**

HRM results of *TOR1A* Exon 5 coding region. Normalized and temperature-shifted melting curves (a) and difference plots (b) for 8 Δ GAG-positive (red) and 88 Δ GAG-negative (blue) samples. Normalized and temperature-shifted melting curves (c) and difference plots (d) for one Δ GAG-positive (red) and five Δ GAG-negative (blue) samples with different concentrations of DNA template (0.1 ng/ μ l, 0.25 ng/ μ l, 0.5 ng/ μ l, 1 ng/ μ l, and 2.5 ng/ μ l; each in duplicate). Normalized and temperature-shifted melting curves (e) and difference plots (f) for Δ GAG-positive (green; one sample, in duplicate), Δ GAG-negative (red; three samples, each in duplicate) and c.863G>A mutation (blue; 1:1 mixtures of template DNA from normals with c.863G>A amplicons) 314 bp amplicons. Normalized and temperature-shifted melting curves (g) and difference plots (h) for Δ GAG-positive (green; one sample, in duplicate), Δ GAG-negative (red; three samples, each in duplicate) and c.863G>A mutation (blue; 1:1 mixtures of template DNA from normals with c.863G>A amplicons) 205 bp amplicons.

Table 2: DYT1 mutations in non-generalized primary dystonia

Reference	Number of subjects with non-generalized primary dystonia	Number with GAG mutations	Phenotypic description of GAG-positive subjects
Valente et al. (1998) [15]	108 (Europe) S = 48, F = 60	3 (2.8%)	#1: S(arms), early-onset, FH+, Jewish #2: F(arm), early-onset, FH-, Jewish #3: F(arm), early-onset, FH+
Klein et al. (1999) [37]	300 (United States, Germany, Italy; late-onset & FH+) S = 7, F = 293	3 (1.0%)	#1: S(both legs & one arm), late-onset, FH+ #2: F(cranial), late-onset, FH+ #3: F(NA), late-onset, FH+, Jewish
Brassat et al. (2000) [39]	90 (France, FH-) S = 21, F = 69	1 (1.1%)	#1: S(leg & trunk), early-onset, FH-
Kamm et al. (2000) [40]	44 (Germany) F = 44 (writer's cramp)	0 (0.0%)	NA
Friedman et al. (2000) [41]	18 (United States) F = 18 (musicians)	0 (0.0%)	NA
Major et al. (2001) [42]	38 (Serbia) M = 1, S = 22, F = 15	2 (5.3%)	#1: S(both arms), early-onset, FH- #2: M(right arm & left leg), early-onset, FH-
Matsumoto et al. (2001) [43]	173 (Japan) M = 4, S = 29, F = 144,	3 (1.7%)	#1: F(arm), early-onset, FH+ #2: F(arm), early-onset, FH+ #3: F(leg), late-onset, FH+
Maniak et al. (2003) [8]	130 (Germany) S = 10, F = 120	0 (0.0%)	NA
Grundmann et al. (2003)[17]	244 (Germany) M = 11, S = 46, F = 187	4 (1.6%)	#1: M(both legs & right arm), early-onset, FH- #2: M(both arms & cranial), late-onset, FH+ #3: S(both arms), early-onset, FH+ #4: S(both arms), early-onset, FH-
Kabakci et al. (2004) [18]	126 (Germany) F + S = 126	0 (0%)	NA
Im et al. (2004) [44]	155 (Korea) S = 21, F = 134	2 (1.3%)	#1: S(arm & shoulder), early-onset, FH+ #2: S(arm & neck), early-onset, FH-
Dhaenens et al. (2005) [45]	150 (France) F = 150	1 (0.7%)	#1: F(arm), onset?, FH+
Lin et al. (2006) [46]	186 (Taiwan) M = 3, S = 47, F = 136	2 (1.1%)	#1: F(leg), early-onset, FH+ #2: S(neck & trunk), late-onset, FH+
Jamora et al. (2006) [47]	54 (Singapore) M = 1, S = 11, F = 41	0 (0.0%)	NA
Naiya et al. (2006) [48]	150 (India) F = 138, S = 12	0 (0%)	NA
Gajos et al. (2007) [31]	48 (Poland) G + S + F = 48	F = 2 (NA)	#1: F(arm), late-onset, FH+ #2: F(arm), early-onset, FH+

G, generalized dystonia; M, multifocal dystonia; S, segmental dystonia; F, focal dystonia; FH, family history of dystonia; and NA, not applicable.

heterogeneous with oftentimes striking intrafamilial and interfamilial variability [28-31]. Indeed, our subject #1 had childhood-onset cervical dystonia with much later development of laryngeal dystonia and writer's cramp, whereas subject #2 manifested dystonia with isolated laryngeal involvement for over 40 yrs. Other remarkable phenotypes described in the literature include onset of focal dystonia at 64 yrs, status dystonicus, and late-onset dystonia precipitated by exposure to a neuroleptic [29,30].

In comparison with several of the studies listed in Table 2, the percentage of Δ GAG mutations was relatively low in our cohort of subjects with non-generalized dystonia. Approximately, 90% of our patients with primary dystonia were non-Jewish Caucasians born in the United States; only 6 Jewish subjects were screened for *TOR1A* Exon 5 mutations. Since the carrier frequency of the classic DYT1 Δ GAG mutation is estimated at 1:1000-1:3000 in Ashkenazi Jews [32] and less than 1:30,000 in non-Jews [33], inclusion of additional Jewish subjects may have increased our percentage of Δ GAG cases.

Our study was limited to interrogation of Exon 5 of *TOR1A* and does not exclude a role for *TOR1A* mutations and/or variants in the etiopathogenesis of late-onset primary dystonia. Single nucleotide polymorphisms (SNPs) within or in close proximity to the 3' UTR of *TOR1A* may be associated with primary focal dystonia [34-36]. Mutations in Exons 1-4 and associations between dystonia phenotypes and *TOR1A* copy number variants and single nucleotide polymorphisms must be interrogated in future studies.

Previous studies of primary dystonia have employed a wide variety of methods for detection of *TOR1A* mutations [13,21,37-49]. For large cohorts, direct sequencing of each sample is expensive, labor intensive, and inefficient. Similarly, previously employed techniques such as PCR-based polyacrylamide gel electrophoresis (PAGE) with silver staining [37], restriction fragment length polymorphism (RFLP) analysis with restriction enzyme BseR1 [38-48] and SSCP (single-strand conformation polymorphism) analysis [13,21], are slow, requiring multiple steps including gel electrophoresis. Although not gel-dependent, denaturing high-performance liquid chromatography (DHPLC) also requires post-PCR handling which is labor-intensive and associated with the risk of well-to-well cross contamination [49].

HRM has recently been introduced as a screening method for mutation detection. HRM is a closed-tube method that can be performed in a rapid, economical, reliable, and high-throughput fashion. In a comparative study, Chou and colleagues showed that HRM is superior to DHPLC

[50]. HRM has been utilized for the detection of germline and somatic mutations as well as SNP genotyping with high sensitivity and specificity [23,51-54]. Other HRM applications include microsatellite analysis, screening for loss of heterozygosity, and DNA methylation analysis.

The utility and efficiency of HRM can be maximized by careful experimental design. In our study, a single pair of primers was designed to cover the entire coding region of *TOR1A* Exon 5 and generated a 314 bp amplicon. Theoretically, differentiation of samples carrying a sequence variation is better with shorter amplicons. In general, amplicons from 50 to 250 bp are ideal for HRM, particularly when employed for SNP and homozygous mutation analysis. However, 100% sensitivity and specificity has been observed with amplicons larger than 600 bp [55]. Thus, the clear separation of 314 bp amplicons harboring heterozygous Δ GAG and c.863G>A mutations was not unexpected.

HRM offers additional advantages over older screening techniques. First, amplicons of interest only require purification prior to follow-up sequencing. There is no need to PCR amplify DNA templates. Second, HRM robustly differentiates genotypes despite moderate differences in well-to-well concentrations of DNA templates. Lastly, Roche's LightCycler® 480 Real-Time PCR system offers 384-well plate capabilities which, when coupled with a robotic workstation, permits completion of very large projects (>10,000 samples) in a single week. Clearly, HRM is well-suited for many candidate gene and SNP-association studies of dystonia and other neurological disorders.

Conclusion

In conclusion, we have developed a fast, efficient and reliable screening method for known mutations (Δ GAG and c.863G>A) within the coding region of *TOR1A* Exon 5 using HRM. HRM showed 100% diagnostic sensitivity and specificity. In a large cohort of patients with non-generalized primary dystonia in the US, *TOR1A* Exon 5 mutations were very uncommon; only two classic DYT1 Δ GAG and no c.863G>A mutations were identified. HRM may be applicable to high-throughput mutation detection in other movement and general neurological disorders.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

MSL designed the study. JX, SG and YZ extracted DNA from blood samples. JX and MSL optimized and implemented the HRM protocol and analyzed HRM data. RWB, JSP, BAR, SDT, MK, RP, AB, ZKW, RJU, PH, DKS, DT, DDT, KPF, RFP and MSL examined research subjects. SDB pro-

vided DNA from subjects with a clinical diagnosis of dystonia. JX and MSL drafted the manuscript. All authors read and approved the final manuscript.

Acknowledgements

This study was supported by the Neuroscience Institute at the University of Tennessee Health Science Center (M.S.L.), Dystonia Medical Research Foundation (M.S.L.) and NIH National Institute of Neurological Disease and Stroke grant R01NS048458 (M.S.L.). At Washington University School of Medicine, work was supported by the NIH National Institute of Neurological Disease and Stroke grants P30NS05710 (Neuroscience Blueprint Grant) and Clinical Sciences Translation Award RR024992, the American Parkinson's Disease Association (APDA) Advanced Research Center, the Greater St. Louis Chapter of the APDA, the Barnes-Jewish Hospital Foundation (Jack Buck Fund for PD Research and the Elliot H. Stein Family Fund), the Missouri Chapter of the Dystonia Research Foundation and the Murphy Fund. At Mayo Clinic Jacksonville, work was supported by the NIH National Institute of Neurological Disease and Stroke Morris K. Udall Center of Excellence for Parkinson Disease Research grant (P50-NS40256). At the Parkinson's & Movement Disorder Institute, work was supported by the Long Beach Memorial Foundation, Orange Coast Memorial Foundation, and the Parkinson's & Movement Disorder Foundation.

We gratefully acknowledge the assistance of C. Lohnes, J. Dennhardt, A. Fitzgerald, E. Heintzen, L. Carpenter, C. Keppel, J. Hartlein, T. Pretorius, A. Strongosky, J. Searcy, H. Lam, and C. Lim.

References

- Fahn S, Marsden CD, Calne DB: **Classification and investigation of dystonia.** In *Movement disorders 2* Edited by: Marsden CD, Fahn S. London: Butterworths; 1987:332-358.
- Fahn S: **Concept and classification of dystonia.** *Adv Neurol* 1988, **50**:1-8.
- Fahn S, Bressman SB, Marsden CD: **Classification of dystonia.** *Adv Neurol* 1998, **78**:1-10.
- Defazio G, Abbruzzese G, Livrea P, Berardelli A: **Epidemiology of primary dystonia.** *Lancet Neurol* 2004, **3**:673-678.
- Duane DD: **Spasmodic torticollis: clinical and biologic features and their implications for focal dystonia.** *Adv Neurol* 1988, **50**:473-492.
- Grandas F, Elston J, Quinn N, Marsden CD: **Blepharospasm: a review of 264 patients.** *J Neurol Neurosurg Psychiatry* 1988, **51**:767-772.
- Chan J, Brin MF, Fahn S: **Idiopathic cervical dystonia: clinical characteristics.** *Mov Disord* 1991, **6**:119-126.
- Maniak S, Sieberer M, Hagenah J, Klein C, Vieregge P: **Focal and segmental primary dystonia in north-western Germany – a clinico-genetic study.** *Acta Neurol Scand* 2003, **107**:228-232.
- Defazio G, Martino D, Aniello MS, Masi G, Abbruzzese G, Lamberti S, Valente EM, Brancati F, Livrea P, Berardelli A: **A family study on primary blepharospasm.** *J Neurol Neurosurg Psychiatry* 2006, **77**:252-254.
- Grundmann K, Laubis-Herrmann U, Dressler D, Vollmer-Haase J, Bauer P, Stuhmann M, Schulte T, Schöls L, Topka H, Riess O: **Lack of mutations in the epsilon-sarcoglycan gene in patients with different subtypes of primary dystonias.** *Mov Disord* 2004, **19**:1294-1297.
- Brashear A, Dobyns WB, de Carvalho Aguiar P, Borg M, Frijns CJ, Gollamudi S, Green A, Guimaraes J, Haake BC, Klein C, Linazasoro G, Münchau A, Raymond D, Riley D, Saunders-Pullman R, Tijssen MA, Webb D, Zaremba J, Bressman SB, Ozelius LJ: **The phenotypic spectrum of rapid-onset dystonia-parkinsonism (RDP) and mutations in the ATP1A3 gene.** *Brain* 2007, **130**:828-835.
- Roze E, Apartis E, Clot F, Dorison N, Thobois S, Guyant-Marchal L, Tranchant C, Damier P, Doummar D, Bahi-Buisson N, André-Obadia N, Maltete D, Echaniz-Laguna A, Pereon Y, Beaugendre Y, Dupont S, De Greslan T, Jedynak CP, Ponsot G, Dussaule JC, Brice A, Dürr A, Vidaliht M: **Myoclonus-dystonia: clinical and electrophysio-**
- logic pattern related to SGCE mutations.** *Neurology* 2008, **70**:1010-1016.
- Ozelius LJ, Hewett JW, Page CE, Bressman SB, Kramer PL, Shalish C, de Leon D, Brin MF, Raymond D, Corey DP, Fahn S, Risch NJ, Buckler AJ, Gusella JF, Breakefield XO: **The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein.** *Nat Genet* 1997, **17**:40-48.
- Gasser T, Windgassen K, Berezna B, Kabus C, Ludolph AC: **Phenotypic expression of the DYT1 mutation: a family with writer's cramp of juvenile onset.** *Ann Neurol* 1998, **44**:126-128.
- Valente EM, Warner TT, Jarman PR, Mathen D, Fletcher NA, Marsden CD, Bhatia KP, Wood NW: **The role of DYT1 in primary torsion dystonia in Europe.** *Brain* 1998, **121**(Pt 12):2335-2339.
- O'Riordan S, Cockburn D, Barton D, Lynch T, Hutchinson M: **Primary torsion dystonia due to the Tor1A GAG deletion in an Irish family.** *Ir J Med Sci* 2002, **171**:31-32.
- Grundmann K, Laubis-Herrmann U, Bauer I, Dressler D, Vollmer-Haase J, Bauer P, Stuhmann M, Schulte T, Schöls L, Topka H, Riess O: **Frequency and phenotypic variability of the GAG deletion of the DYT1 gene in an unselected group of patients with dystonia.** *Arch Neurol* 2003, **60**:1266-1270.
- Kabakci K, Hedrich K, Leung JC, Mitterer M, Vieregge P, Lencer R, Hagenah J, Garrels J, Witt K, Klostermann F, Svetel M, Friedman J, Kostic V, Bressman SB, Breakefield XO, Ozelius LJ, Pramstaller PP, Klein C: **Mutations in DYT1: extension of the phenotypic and mutational spectrum.** *Neurology* 2004, **62**:395-400.
- Gambaran M, Valente EM, Liberini P, Barrano G, Bonizzato A, Padovani A, Moretto G, Fiorio M, Dallapiccola B, Smania N, Fiaschi A, Tinazzi M: **Atypical phenotypes and clinical variability in a large Italian family with DYT1-primary torsion dystonia.** *Mov Disord* 2006, **21**:1782-1784.
- Zirn B, Grundmann K, Huppke P, Puthenparampil J, Wolburg H, Riess O, Müller U: **Novel TOR1A mutation p.Arg288Gln in early-onset dystonia (DYT1).** *J Neurol Neurosurg Psychiatry* 2008, **79**:1327-1330.
- Leung JC, Klein C, Friedman J, Vieregge P, Jacobs H, Doheny D, Kamm C, DeLeon D, Pramstaller PP, Penney JB, Eisengart M, Jankovic J, Gasser T, Bressman SB, Corey DP, Kramer P, Brin MF, Ozelius LJ, Breakefield XO: **Novel mutation in the TOR1A (DYT1) gene in atypical early onset dystonia and polymorphisms in dystonia and early onset parkinsonism.** *Neurogenetics* 2001, **3**:133-143.
- Klein C, Liu L, Doheny D, Kock N, Müller B, de Carvalho Aguiar P, Leung J, de Leon D, Bressman SB, Silverman J, Smith C, Danis F, Morrison C, Walker RH, Velickovic M, Schwinger E, Kramer PL, Breakefield XO, Brin MF, Ozelius LJ: **Epsilon-sarcoglycan mutations found in combination with other dystonia gene mutations.** *Ann Neurol* 2002, **52**:675-679.
- Wittwer CT, Reed GH, Gundry CN, Vandersteen JG, Pryor RJ: **High-resolution genotyping by amplicon melting analysis using LCGreen.** *Clin Chem* 2003, **49**:853-860.
- Bressman SB: **Dystonia genotypes, phenotypes, and classification.** *Adv Neurol* 2004, **94**:101-107.
- Bressman SB, Sabatti C, Raymond D, de Leon D, Klein C, Kramer PL, Brin MF, Fahn S, Breakefield X, Ozelius LJ, Risch NJ: **The DYT1 phenotype and guidelines for diagnostic testing.** *Neurology* 2000, **54**:1746-1752.
- Klein C, Brin MF, de Leon D, Limborska SA, Ivanova-Smolenskaya IA, Bressman SB, Friedman A, Markova ED, Risch NJ, Breakefield XO, Ozelius LJ: **De novo mutations (GAG deletion) in the DYT1 gene in two non-Jewish patients with early-onset dystonia.** *Hum Mol Genet* 1998, **7**:1133-1136.
- Hjermind LE, Werdelin LM, Sorensen SA: **Inherited and de novo mutations in sporadic cases of DYT1-dystonia.** *Eur J Hum Genet* 2002, **10**:213-216.
- Leube B, Kessler KR, Ferbert A, Ebke M, Schwendemann G, Erbguth F, Benecke R, Auburger G: **Phenotypic variability of the DYT1 mutation in German dystonia patients.** *Acta Neurol Scand* 1999, **99**:248-251.
- Opal P, Tintner R, Jankovic J, Leung J, Breakefield XO, Friedman J, Ozelius L: **Intrafamilial phenotypic variability of the DYT1 dystonia: from asymptomatic TOR1A gene carrier status to dystonic storm.** *Mov Disord* 2002, **17**:339-345.
- Edwards M, Wood N, Bhatia K: **Unusual phenotypes in DYT1 dystonia: a report of five cases and a review of the literature.** *Mov Disord* 2003, **18**:706-711.

31. Gajos A, Piaskowski S, Slawek J, Ochudło S, Opala G, Łobińska A, Honczarenko K, Budrewicz S, Koszewicz M, Pelszyńska B, Liberski PP, Bogucki A: **Phenotype of the DYT1 mutation in the TOR1A gene in a Polish population of patients with dystonia. A preliminary report.** *Neurol Neurochir Pol* 2007, **41**:487-494.
32. Risch N, de Leon D, Ozelius L, Kramer P, Almasy L, Singer B, Fahn S, Breakefield X, Bressman S: **Genetic analysis of idiopathic torsion dystonia in Ashkenazi Jews and their recent descent from a small founder population.** *Nat Genet* 1995, **9**:152-159.
33. Frédéric M, Lucarz E, Monino C, Saquet C, Thorel D, Claustres M, Tuffery-Giraud S, Collod-Bérour G: **First determination of the incidence of the unique TOR1A gene mutation, c.907delGAG, in a Mediterranean population.** *Mov Disord* 2007, **22**:884-888.
34. Clarimon J, Asgeirsson H, Singleton A, Jakobsson F, Hjaltonson H, Hardy J, Sveinbjornsdottir S: **TorsinA haplotype predisposes to idiopathic dystonia.** *Ann Neurol* 2005, **57**:765-767.
35. Kamm C, Asmus F, Mueller J, Mayer P, Sharma M, Muller UJ, Beckert S, Ehling R, Illig T, Wichmann HE, Poewe W, Mueller JC, Gasser T: **Strong genetic evidence for association of TOR1A/TOR1B with idiopathic dystonia.** *Neurology* 2006, **67**:1857-1859.
36. Hague S, Klaffke S, Clarimon J, Hemmer B, Singleton A, Kupsch A, Bandmann O: **Lack of association with torsinA haplotype in German patients with sporadic dystonia.** *Neurology* 2006, **66**:951-952.
37. Klein C, Friedman J, Bressman S, Vieregge P, Brin MF, Pramstaller PP, De Leon D, Hagenah J, Sieberer M, Fleet C, Kiely R, Xin W, Breakefield XO, Ozelius LJ, Sims KB: **Genetic testing for early-onset torsion dystonia (DYT1): introduction of a simple screening method, experiences from testing of a large patient cohort, and ethical aspects.** *Genet Test* 1999, **3**:323-328.
38. Kamm C, Castelon-Konkiewitz E, Naumann M, Heinen F, Brack M, Nebe A, Ceballos-Baumann A, Gasser T: **GAG deletion in the DYT1 gene in early limb-onset idiopathic torsion dystonia in Germany.** *Mov Disord* 1999, **14**:681-683.
39. Brassat D, Camuzat A, Vidailhet M, Feki I, Jedynak P, Klap P, Agid Y, Dürr A, Brice A: **Frequency of the DYT1 mutation in primary torsion dystonia without family history.** *Arch Neurol* 2000, **57**:333-335.
40. Kamm C, Naumann M, Mueller J, Mai N, Riedel L, Wissel J, Gasser T: **The DYT1 GAG deletion is infrequent in sporadic and familial writer's cramp.** *Mov Disord* 2000, **15**:1238-1241.
41. Friedman JR, Klein C, Leung J, Woodward H, Ozelius LJ, Breakefield XO, Charness ME: **The GAG deletion of the DYT1 gene is infrequent in musicians with focal dystonia.** *Neurology* 2000, **55**:1417-1418.
42. Major T, Svetel M, Romac S, Kostić VS: **DYT1 mutation in primary torsion dystonia in a Serbian population.** *J Neurol* 2001, **248**:940-943.
43. Matsumoto S, Nishimura M, Kaji R, Sakamoto T, Mezaki T, Shimazu H, Murase N, Shibasaki H: **DYT1 mutation in Japanese patients with primary torsion dystonia.** *Neuroreport* 2001, **12**:793-795.
44. Im JH, Ahn TB, Kim KB, Ko SB, Jeon BS: **DYT1 mutation in Korean primary dystonia patients.** *Parkinsonism Relat Disord* 2004, **10**:421-423.
45. Dhaenens CM, Krystkowiak P, Douay X, Charpentier P, Bele S, Destée A, Sablonnière B: **Clinical and genetic evaluation in a French population presenting with primary focal dystonia.** *Mov Disord* 2005, **20**:822-825.
46. Lin YW, Chang HC, Chou YH, Chen RS, Hsu WC, Wu WS, Weng YH, Lu CS: **DYT1 mutation in a cohort of Taiwanese primary dystonias.** *Parkinsonism Relat Disord* 2006, **12**:15-19.
47. Jamora RD, Tan EK, Liu CP, Kathirvel P, Burgunder JM, Tan LC: **DYT1 mutations amongst adult primary dystonia patients in Singapore with review of literature comparing East and West.** *J Neurol Sci* 2006, **247**:35-37.
48. Naiya T, Biswas A, Neogi R, Datta S, Misra AK, Das SK, Ray K, Ray J: **Clinical characterization and evaluation of DYT1 gene in Indian primary dystonia patients.** *Acta Neurol Scand* 2006, **114**:210-215.
49. Yang JF, Li JY, Li YJ, Wu T, Zhang YL, Chen B: **DYT1 mutations amongst early onset primary dystonia patients in China.** *Chin Med Sci J* 2008, **23**:38-43.
50. Chou LS, Lyon E, Wittwer CT: **A comparison of high-resolution melting analysis with denaturing high-performance liquid chromatography for mutation scanning: cystic fibrosis transmembrane conductance regulator gene as a model.** *Am J Clin Pathol* 2005, **124**:330-338.
51. Reed GH, Kent JO, Wittwer CT: **High-resolution DNA melting analysis for simple and efficient molecular diagnostics.** *Pharmacogenomics* 2007, **8**:597-608.
52. Montgomery J, Wittwer CT, Kent JO, Zhou L: **Scanning the cystic fibrosis transmembrane conductance regulator gene using high-resolution DNA melting analysis.** *Clin Chem* 2007, **53**:1891-1898.
53. Kennerson ML, Warburton T, Nelis E, Brewer M, Polly P, De Jonghe P, Timmerman V, Nicholson GA: **Mutation scanning the GJB1 gene with high-resolution melting analysis: implications for mutation scanning of genes for Charcot-Marie-Tooth disease.** *Clin Chem* 2007, **53**:349-352.
54. De Leeneer K, Coene I, Poppe B, De Paepe A, Claes K: **Rapid and sensitive detection of BRCA1/2 mutations in a diagnostic setting: comparison of two high-resolution melting platforms.** *Clin Chem* 2008, **54**:982-989.
55. Reed GH, Wittwer CT: **Sensitivity and specificity of single-nucleotide polymorphism scanning by high-resolution melting analysis.** *Clin Chem* 2004, **50**:1748-1754.

Pre-publication history

The pre-publication history for this paper can be accessed here:

<http://www.biomedcentral.com/1471-2350/10/24/prepub>

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

